CBIO

13.0000.70%
JM

Jonathan McNeill

President & COO

Dr. Jonathan McNeill, M.D., is President & COO of Crescent Biopharma, Inc. from March 2025. Dr. McNeill is Venture Partner of Forbion Capital Partners B.V. from 2025. Dr. McNeill focuses on early-stage, biotech. Dr. McNeill was Partner of Forbion Capital Partners B.V. from January 2025 to 2025. At Forbion, Dr. McNeill supports the Ventures Fund strategy, focusing on building and enabling earlier-stage biotech companies, leveraging his extensive experience in business development, capital raises and initial public offerings. Dr. McNeill was Chief Business Officer of Dyne Therapeutics, Inc. from July 2023 to September 2024. Dr. McNeill was Senior Vice President of Business Development of Dyne Therapeutics, Inc. from July 2021 to July 2023. Dr. McNeill was Vice President of Business Development of Dyne Therapeutics, Inc. Dr. McNeill was employed at Dyne Therapeutics, Inc. until September 2024. During his tenure at Dyne, Dr. McNeill was instrumental in the biotech's transformation, leading business development efforts and executing multiple financings totaling. He was also a key member of the executive team that advanced several neuromuscular disease programs through clinical proof-of-concept trials. Before joining Dyne Therapeutics, Dr. McNeill held leadership roles at Editas Medicine, where he played a significant role in the execution of the company’s IPO and its oncology collaboration with Juno Therapeutics. He also has experience as a member of Boston Consulting Group’s healthcare practice, where he contributed to strategic initiatives in the life sciences sector. Dr. McNeill has M.D. from University of Pennsylvania and B.A. in Economics & Public Policy from University of North Carolina.

Positions